Tumor Model Portfolio Service for Streamlined Functional CAR-T Screening

Online Inquiry

Background Service What we can offer Workflow Highlights FAQsContact

Creative Biolabs offers a comprehensive Tumor Model Portfolio Service designed to streamline functional CAR-T screening and accelerate immunotherapy drug discovery. Our integrated platform combines high-fidelity 3D tumor organoids, syngeneic mouse models, and humanized systems to address poor in vitro–in vivo correlation and high attrition in solid tumor targeting. By enabling systematic evaluation of CAR-T efficacy, persistence, and safety across complementary model systems, we help identify high-potency lead candidates with greater translational confidence. This service supports efficient candidate prioritization, reduces development timelines, and improves decision-making throughout preclinical CAR-T development.

Introduction

Adoptive T-cell therapy has revolutionized hematologic oncology, yet solid tumors remain a challenge due to antigen escape and T-cell exhaustion. Traditional 2D cultures often fail to predict clinical efficacy because they lack the spatial and cellular complexity of the tumor microenvironment. High-throughput screening (HTS) integrated with 3D organoids and humanized mouse models offers a more predictive transition from bench to bedside.

Fig.1 Functional characteristics of CAR T cells. (OA Literature) Fig.1 Functional parameters of CAR T cells.¹

Service

Navigating the complexities of adoptive T-cell therapy requires more than just standard assays. Our service provides the precision infrastructure needed to de-risk your pipeline before clinical entry. By utilizing our portfolio, you can expect:

Reliable Lead Prioritization: Rank your CAR constructs based on functional performance in models that accurately simulate the solid tumor barrier and immunosuppressive microenvironment.
Predictive Safety Profiling: Early identification of potential off-target toxicities and cytokine release syndrome risks using our humanized immune-reconstitution platforms.
Mechanistic Clarity: Detailed data on CAR-T infiltration, metabolic persistence, and "antigen spread" to justify moving forward with specific clinical candidates.

Discover How We Can Help - Request a Consultation.

What we can offer

We provide a comprehensive array of technology platforms designed to mirror the biological reality of cancer patients:

3D Tumor-Derived Model: Scaffolds that capture the genetic heterogeneity and spatial architecture of patient-specific tumors.
Syngeneic Mouse Models: For evaluating "armored" CAR designs in an intact, immune-competent environment to study endogenous immune recruitment.
Humanized Mice (HSC-HM): NSG/NRG-based models with reconstituted human hematopoietic systems for high-fidelity toxicity and efficacy testing.
In Vitro Rechallenge Platforms: Automated sequential killing assays to identify CAR-T products resistant to chronic exhaustion.
Cell Functional Analytics: Integration of RNA sequencing analysis with functional readouts to map the transcriptomic signatures of high-performing cells.

Our Process

Workflow of Tumor Model Portfolio. (Creative Biolabs Original)

Final Deliverables:

Potency Report: Cytotoxicity kinetics, cytokine release, and expansion data.

Phenotypic Analysis: Flow cytometry and/or RNA sequencing profiling of differentiation and exhaustion.

Pathological Validation: IHC images demonstrating CAR-T infiltration and tumor regression.

Core Benefits

One-stop functional screening service from initial in vitro validation to advanced humanized in vivo models.
Fully customized assay designs, including optimized effector / target ratios, multi-antigen targeting evaluations, and specific TAA-density modeling.
Rigorous aseptic and quality control systems ensure consistent results across different donor batches and cell lines.
Predictive syngeneic models to evaluate "antigen spread" and the recruitment of endogenous anti-tumor immunity.

FAQs

Q1: Why use syngeneic models for human CAR-T therapies?

A1: Syngeneic models feature an intact immune system, essential for studying "antigen spread" and interactions with endogenous T cells and macrophages. This provides critical insights into the long-term protective immunity your therapy may induce.

Q2: Are your platforms compatible with next-gen "armored" or "logic-gated" CARs?

A2: Absolutely. Our portfolio is optimized for complex constructs, including those with engineered cytokine secretion or dual-antigen recognition. Our high-throughput systems efficiently handle multiple variables to identify the most effective design.

Q3: How do you manage CAR-T donor variability?

A3: We utilize standardized manufacturing and can incorporate multiple donor batches per study to address biological variability. Our computational reporting integrates these results to provide a clear ranking of construct potency.

Partner with Us

Creative Biolabs provides an end-to-end Tumor Model Portfolio Service tailored for the rigorous demands of functional CAR-T screening. By combining high-fidelity 3D tumor models, humanized immune-system and advanced single-cell analytics, we enable researchers to overcome the "solid tumor barrier" and identify the safest, most effective clinical leads. Our integrated workflow ensures data-driven decisions that save time, reduce costs, and maximize the success of your adoptive cell therapy pipeline.

Ready to accelerate your CAR-T discovery? Our team of specialists is standing by to discuss your project requirements and provide a customized screening strategy. Contact us to discuss your specific target.

Reference

Si, Xiaohui et al. "Preclinical Evaluation of CAR T Cell Function: In Vitro and In Vivo Models." International journal of molecular sciences vol. 23,6 3154. 15 Mar. 2022. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/ijms23063154

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.